Cellectar Biosciences (CLRB) EBIT (2010 - 2026)
Cellectar Biosciences (CLRB) posted EBIT of -$5.7 million for Q4 2025, down 17.32% sequentially from -$4.9 million in Q3 2025, and up 55.35% YoY from -$3.7 million in Q4 2024.
Cellectar Biosciences (CLRB) EBIT (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported EBIT for 16 years, with the latest figure at -$5.7 million in Q4 2025.
- Quarterly EBIT rose 55.35% year-over-year to -$5.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$23.0 million (up 55.62% YoY) and the FY2025 annual result came in at -$23.0 million, up 55.62% from the prior year.
- EBIT eased to -$5.7 million in Q4 2025 per CLRB's latest filing, from -$4.9 million in the prior quarter.
- Over five years, EBIT peaked at -$4.9 million in Q3 2025 and troughed at -$13.7 million in Q2 2024.
- A 5-year average of -$8.3 million and a median of -$7.4 million in 2022 frame the typical range for EBIT.
- The sharpest annual moves came in 2023 and 2025: EBIT sank 69.05% in 2023, then surged 63.6% in 2025.
- Over 5 years, EBIT stood at -$5.9 million in 2021, then retreated by 25.31% to -$7.4 million in 2022, then tumbled by 69.05% to -$12.5 million in 2023, then decreased by 1.57% to -$12.7 million in 2024, then surged by 55.35% to -$5.7 million in 2025.
- According to Business Quant data, EBIT over the past three periods registered -$5.7 million, -$4.9 million, and -$6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Cellectar Biosciences | 6.63 Mn | 6.63 Mn | - | -7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.20 Mn |
| Dec 31, 2025 | -5.69 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Jun 30, 2025 | -6.04 Mn |
| Mar 31, 2025 | -6.40 Mn |
| Dec 31, 2024 | -12.74 Mn |
| Sep 30, 2024 | -13.33 Mn |
| Jun 30, 2024 | -13.70 Mn |
| Mar 31, 2024 | -12.00 Mn |
| Dec 31, 2023 | -12.55 Mn |
| Sep 30, 2023 | -9.41 Mn |
| Jun 30, 2023 | -8.29 Mn |
| Mar 31, 2023 | -8.71 Mn |
| Dec 31, 2022 | -7.42 Mn |
| Sep 30, 2022 | -7.82 Mn |
| Jun 30, 2022 | -7.44 Mn |
| Mar 31, 2022 | -6.14 Mn |
| Dec 31, 2021 | -5.92 Mn |
| Sep 30, 2021 | -5.82 Mn |
| Jun 30, 2021 | -6.03 Mn |